Phase I trial results showed tolerable side effects.<ref>{{cite journal |doi=10.1111/j.1365-2141.2008.07013.x |title=Alternate day pomalidomide retains anti-myeloma effect with reduced adverse events and evidence of in vivo immunomodulation |year=2008 |last1=Streetly |first1=Matthew J. |last2=Gyertson |first2=Kylie |last3=Daniel |first3=Yvonne |last4=Zeldis |first4=Jerome B. |last5=Kazmi |first5=Majid |last6=Schey |first6=Stephen A. |journal=British Journal of Haematology |volume=141 |pages=41â€“51 |pmid=18324965 |issue=1}}</ref>
